Liver transplantation in glycogen storage disease type Ib: The role of SGLT2 inhibitors

Abstract

We report on liver transplantation in two patients with GSD Ib on treatment with empagliflozin. The use of this SGLT2 inhibitor resulted in a marked decrease of 1,5-anhydroglucitol which has an important role in the development of neutropenia in this condition. As intended, this caused a significant rise of neutrophil numbers. Liver transplantation alone did not produce the desired effect and our observation argues for continuing SGLT2 inhibitor treatment after transplantation.

Keywords

• Glycogen storage disease Ib
• GSD1b
• Liver transplantation
• SGLT2 inhibitor
• Empagliflozin